Overview of mutations identified by targeted sequencing. (A) Gene-specific prevalence of CH mutations. (B) Number of patients with 1, 2, 3, or 4 mutations. (C) Age distribution of 237 patients according to CH status. (D) CH prevalence according to prior exposure to chemotherapy. DDR, DNA-damage repair machinery.